Shots: Boehringer Ingelheim to acquire all shares of NBE-Therapeutics for ~$1.434B which include contingent clinical and regulatory milestones. The transaction is expected to be closed in Q1’21 The acquisition will […]readmore
Tags : Boehringer Ingelheim
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it Life sciences companies are putting all of their efforts […]readmore
Healthy animals contribute to the elimination of hunger and sustainable food production. The diseases that affect animal health also affect humans. Tackling them while they are present in animals not […]readmore
Shots: The P-II trial will assess BI 764198 (qd for ~4wks.) in patients hospitalized for COVID-19 with expected enrollment initiation in Oct’2020. The 1EPs will be the percentage of patients […]readmore
Shots: The companies present the findings from a new exploratory sub-analysis of the P-III EMPEROR-Reduced study demonstrating that Jardiance (empagliflozin) reduced the risk of adverse CV by 25% and kidney […]readmore
Shots: Real-world study shows the effectiveness and safety of 2L Gilotrif following 1L IO plus CT in the treatment of squamous cell carcinoma of the lung Results: Median overall TOT […]readmore
Shots: The P-II study involves assessing of BI 425809 (4 oral doses, qd) vs PBO over 12wks. treatment period in schizophrenia patients. The results are presented at the 33rd ECNP […]readmore
Shots: Click to receive $500M as up front, funding for research and development activities, clinical, regulatory & commercial milestones along with royalties on sales of CT-155 globally, will lead research […]readmore
Shots: The companies discontinue the P-IIa study assessing BI 1467335 vs PBO in 79 patients with moderately severe to severe NPDR without CIDME for 12wks. treatment period with an additional […]readmore
Shots: BiomX will generate metagenomic data of gut microbiome samples obtained from IBD patients with the focus of identifying biomarkers using the XMarker platform Boehringer Ingelheim gets an option to […]readmore